Chemotherapy-Induced Anemia Pipeline: Pioneering Treatments and Leading Companies Revolutionizing CIA Therapy | DelveInsight

The landscape for treating chemotherapy-induced anemia is evolving rapidly, driven by the development of novel therapies aimed at addressing the unmet needs of patients suffering from anemia induced by cancer treatments. Chemotherapy-induced anemia, a common and debilitating side effect of chemotherapy, results from the suppression of bone marrow and a decrease in red blood cell production, leading to fatigue, weakness, and reduced quality of life for cancer patients. Biopharmaceutical companies such as FibroGen, Zydus Cadila, and SBI Pharmaceuticals are at the forefront, exploring innovative therapeutic options that include erythropoiesis-stimulating agents (ESAs), iron-replenishing therapies, and novel biologics targeting underlying pathways involved in red blood cell production.

DelveInsight's "Chemotherapy-Induced Anemia - Pipeline Insight, 2025" offers a detailed evaluation of the clinical and preclinical development pipeline, providing insights into emerging drug candidates, their mechanisms of action, trial progress, and anticipated regulatory timelines. The report explores a range of investigational therapies, from new-generation ESAs to oral iron therapies and novel biologics, all designed to enhance red blood cell production and reduce the need for blood transfusions in CIA patients.

This pipeline assessment delivers a comprehensive overview of the drug development landscape by analyzing clinical phases, therapeutic classes, administration routes, and trial geographies. Additionally, the report outlines critical unmet needs, strategic partnerships, regulatory designations, and market trends that are poised to shape the future of CIA treatment, providing key insights into the evolving therapeutic options available to manage this significant complication in cancer care.

Interested in learning more about the current treatment landscape and the key drivers shaping the chemotherapy-induced anemia pipeline? Click here: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Chemotherapy-Induced Anemia Pipeline Report
• DelveInsight's chemotherapy-induced anemia pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for chemotherapy-induced anemia treatment.
• The leading chemotherapy-induced anemia companies include FibroGen, Zydus Cadila, SBI Pharmaceuticals, and others are evaluating their lead assets to improve the chemotherapy-induced anemia treatment landscape.
• Key chemotherapy-induced anemia pipeline therapies in various stages of development include Roxadustat, Desidustat, Aminolevulinic acid, and others.
• In April 2025, Cellenkos® Inc., a clinical-stage biotech company specializing in allogeneic, off-the-shelf T regulatory (Treg) cell therapies for inflammatory diseases and autoimmune disorders, announced that the FDA had granted Orphan Drug Designation to its innovative cell therapy product, CK0801.
• In February 2025, FibroGen and AstraZeneca announced that AstraZeneca would acquire FibroGen's China operations for $160 million, gaining full commercialization rights to roxadustat in the region. Roxadustat, a HIF-PH inhibitor already approved in China for anemia associated with chronic kidney disease, is currently under regulatory review for the treatment of chemotherapy-induced anemia (CIA), potentially expanding its indication and reinforcing its relevance in the CIA treatment landscape.

Request a sample and discover the recent breakthroughs happening in the chemotherapy-induced anemia pipeline landscape @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Anemia Overview
Chemotherapy-induced anemia (CIA) results from blood loss, bone marrow disruption, and iron deficiency caused by chemotherapy. It significantly impacts treatment by limiting therapy, causing fatigue, and reducing quality of life. CIA varies based on factors like chemotherapy type, cancer stage, hemoglobin levels, and timing of interventions (e.g., transfusions, iron, erythropoietin). Common in hematologic cancers, CIA treatment aims to alleviate symptoms and improve quality of life, with therapies including red blood cell transfusions, erythropoietin-stimulating agents (ESAs), and iron supplementation. Proper management can enhance chemotherapy effectiveness.

Find out more about chemotherapy-induced anemia medication @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Anemia Treatment Analysis: Drug Profile
Roxadustat: FibroGen
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor developed by FibroGen. It stimulates coordinated erythropoiesis by elevating endogenous erythropoietin levels, enhancing iron availability, and lowering hepcidin levels. Clinical studies have shown that roxadustat can boost red blood cell production while keeping erythropoietin levels within a near-normal physiologic range, even in CKD patients with inflammation and without the need for intravenous iron. Roxadustat is approved for treating anemia in CKD patients, both on and off dialysis, in China, Japan, South Korea, Europe, and Chile. Although the FDA issued a Complete Response Letter (CRL) in August 2021 for its NDA targeting CKD anemia in the U.S., roxadustat is still under Phase III development for anemia associated with myelodysplastic syndromes (MDS) and is in Phase II trials for chemotherapy-induced anemia (CIA) in the U.S.

SPP-003: SBI Pharmaceuticals
SBI Pharmaceuticals is developing SPP-003, a formulation containing 5-aminolevulinic acid (5-ALA), for the treatment of chemotherapy-induced anemia. The company has submitted an Investigational New Drug (IND) application to the U.S. FDA to initiate a Phase I clinical trial. 5-ALA, a naturally occurring amino acid synthesized in mitochondria, plays a key role in energy metabolism through its involvement in heme and cytochrome production. Its levels decline with age. 5-ALA is found in foods like radish sprouts, red wine, and byproducts such as shochu distillation remnants. The compound is believed to enhance hematopoietic function, making it a promising candidate for alleviating anemia in cancer patients undergoing chemotherapy.

Learn more about the novel and emerging chemotherapy-induced anemia pipeline therapies @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Anemia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Chemotherapy-Induced Anemia Pipeline Report
• Coverage: Global
• Key Chemotherapy-Induced Anemia Companies: FibroGen, Zydus Cadila, SBI Pharmaceuticals, and others.
• Key Chemotherapy-Induced Anemia Pipeline Therapies: Roxadustat, Desidustat, Aminolevulinic acid, and others.

Dive deep into rich insights for drugs used for chemotherapy-induced anemia treatment; visit @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Chemotherapy-Induced Anemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chemotherapy-Induced Anemia Pipeline Therapeutics
6. Chemotherapy-Induced Anemia Pipeline: Late-Stage Products (Phase III)
7. Chemotherapy-Induced Anemia Pipeline: Mid-Stage Products (Phase II)
8. Chemotherapy-Induced Anemia Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.